Dr. Chang is an immunology researcher, whose career spans across academia and industry. His early research in the Immunoglobulin E (IgE) pathway and antibody-based therapeutics led to the development of omalizumab (Xolair®), a highly successful mAb medicine that has been approved for the treatment of severe allergic asthma and severe chronic spontaneous urticarial (CSU). He is also a co-inventor of the advanced generation anti-IgE mAb, UB-221.
Dr. Chang is the co-founder of Tanox, a biopharmaceutical company specialized in anti-IgE therapies for the treatment of allergic diseases and acquired by Genentech. Dr. Chang returned to his alma mater National Tsing Hua University in Taiwan in 1996 and served as the Dean (1996–1999) of the College of Life Sciences. Dr. Chang was appointed by the Taiwanese government as the Chief Executive Officer of the Development Center for Biotechnology (DCB) in 2000, and served as a Science and Technology Advisor of the Executive Yuan from 2002 to 2006. From 2006 to 2016, he was tenured as a Distinguished Research Fellow at the Genomics Research Center, Academia Sinica, and a distinguished Visiting Chair of Genomics Research Center at Academia Sinica since 2016. He founded Immunwork, Inc. in 2014. Dr. Chang received both his B.S. and M.S. in chemistry from National Tsing Hua University in 1972 and obtained his Ph.D. in cell and developmental biology from Harvard University in 1977. He completed his postdoctoral fellow training at Center for Cancer Research, M.I.T., from 1977 to 1980.